Using targeted therapy to treat hereditary colorectal cancer by focusing on DNA mismatches
Official title: Targeting DNA Mismatches for Auger Electron Radiotherapy
Funded at Hunter College · NIH-10751210 · Data updated 2026-11-12
This study is exploring a new way to treat hereditary colorectal cancer by using a special technology that targets and fixes mistakes in DNA that can cause tumors, which might make radiation therapy work better for patients with this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hunter College NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 8, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $457,607 |
| NIH project number | 1R21CA280595-01A1 |
| Project ID | NIH-10751210 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hereditary non-polyposis colorectal cancer or those with known mismatch repair deficiencies.
✕Less likely to help
Patients without hereditary colorectal cancer or those whose cancer is not associated with DNA mismatch repair deficiencies may not benefit from this research.
What this research studies
This research investigates a novel approach to treating hereditary colorectal cancer by targeting mismatched DNA base pairs that can lead to tumor development. The study utilizes a technology called metalloinsertors, which bind specifically to these mismatches and disrupt their formation, potentially enhancing the effectiveness of radiotherapy. By employing iodine-123, an Auger electron-emitting radionuclide, the research aims to develop a targeted radiotherapeutic that could selectively destroy cancer cells with DNA repair deficiencies. Patients with hereditary non-polyposis colorectal cancer may benefit from this innovative treatment strategy.
Why it matters
Potential benefit: If successful, this research could provide a new targeted treatment option for patients with hereditary colorectal cancer, improving their outcomes.
How similar studies have gone: While the approach of using metalloinsertors is relatively novel, previous research has shown promise in targeting DNA mismatches for therapeutic purposes.
Where this research is happening
-
Hunter College
New York, United States Active
Researchers
- Principal investigator: Zeglis, Brian Matthew — Hunter College
- Study coordinator: Zeglis, Brian Matthew
Related research
Other NIH-funded projects on the same topics.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A computer program helps plan radiation therapy for cervical and head-and-neck cancer patients to make treatments faster and more accurate.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A United Kingdom study is testing AI software that helps plan radiotherapy for cervical and head-and-neck cancer patients to save time and reduce the workload for clinicians in low-resource settings.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A UK research team is testing an AI-based software to automatically outline cancer areas and plan radiation beams to speed up treatment for cervical and head-and-neck cancers in LMICs.
-
AI-Powered Radiotherapy Planning for Cervical and Head & Neck Cancer
A new AI tool helps plan radiation therapy for cervical and head-and-neck cancers to save time and reduce the need for specialized staff.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A UK study from University College London uses AI to plan radiotherapy for cervical and head-and-neck cancers to save time and reduce the need for specialized staff, aiming to help patients in LMICs.
-
AI-powered radiotherapy planning for cervical and head & neck cancer
A non-randomized study will test an AI system that helps plan radiotherapy for cervical and head & neck cancers to save time and resources in LMICs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.